CoChat
Sign Up
Cited by 223Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyHeat shock proteins research

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice

Open access
Caballero, Benjamin, Bourdenx, Mathieu, Luengo, Enrique, Diaz, Antonio, Sohn, Peter Dongmin, Chen, Xu, Wang, Chao, Juste, Yves R., Wegmann, Susanne, Patel, Bindi, Young, Zapporah T., Kuo, Szu Yu, Rodriguez-Navarro, Jose Antonio, Shao, Hao, Lopez, Manuela G., Karch, Celeste M., Goate, Alison M., Gestwicki, Jason E., Hyman, Bradley T., Gan, Li, Cuervo, Ana Maria·2021·Nature Communications
DOI 10.1038/s41467-021-22501-9PMC PMC8047017
Open this paper in CoChat — free accountOpen PDF

Abstract

Disrupted homeostasis of the microtubule binding protein tau is a shared feature of a set of neurodegenerative disorders known as tauopathies. Acetylation of soluble tau is an early pathological event in neurodegeneration. In this work, we find that a large fraction of neuronal tau is degraded by chaperone-mediated autophagy (CMA) whereas, upon acetylation, tau is preferentially degraded by macroautophagy and endosomal microautophagy. Rerouting of acetylated tau to these other autophagic pathways originates, in part, from the inhibitory effect that acetylated tau exerts on CMA and results in its extracellular release. In fact, experimental blockage of CMA enhances cell-to-cell propagation of pathogenic tau in a mouse model of tauopathy. Furthermore, analysis of lysosomes isolated from brains of patients with tauopathies demonstrates similar molecular mechanisms leading to CMA dysfunction. This study reveals that CMA failure in tauopathy brains alters tau homeostasis and could contribute to aggravate disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-22501-9

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Acetylated tau is degraded by macroautophagy. a Brain slices from the mouse cortex or midbrain were incubated in the presence or absence of NH4Cl 20 mM and leupeptin 200 µM (N/L) or 3-methyladenine (3MA) 10 mM for 4 h at 37 °C and blotted for the indicated proteins. Right: Quantification of total tau (left) [Degradation pathway effect: F(2,78) = 14.31, p < 0.0001], acetylated tau (Ac-Tau; middle) [Degradation pathway effect: F(2,78) = 12.22, p < 0.0001], and fraction of tau degraded by macroautophagy (MA) [Tau status effect: F(1,52) = 507.2, p < 0.0001], n = 15 (for cortex) and 13 (for midbrain) mice per genotype. Controls of the selectivity of the acetylated antibody using brains from tau knockout mice and of the efficiency of the inhibitors are shown in Supplemental Fig. 1a, b. b–e Brain slices from wild-type (WT) and Atg7 knockout mice (ATG7KO) cortex or midbrain were incubated as in a and blotted for the indicated proteins. b Representative immunoblots. c Quantification of total and acetylated tau in two brain regions (cortex and midbrain) [Genotype effect: F(1,28) = 174, p < 0.0001]. d Changes of acetylated tau levels in both mice groups in the cortex (left) [Combined effect: F(2,42) = 4.280, p = 0.0203] and midbrain (right) [Degradation pathway effect: F(2,42) = 3.707, p = 0.0329], n = 3. Changes in total tau are shown in Supplemental Fig. 1d. e Flux of total and acetylated tau in the cortex (left) and midbrain (right) calculated as the fold increase in tau levels upon addition of N/L. f High content microscopy representative images of a mouse neuroblastoma cell line Neuro-2a (N2a) transduced with mCherry-GFP-LC3 and transfected with unmodified FLAG-wild-type Tau (WT) or acetylation-mimetic FLAG-K274,281Q tau (KQ) and maintained in the presence or absence of serum for 4 h. Nuclei are highlighted with DAPI in blue. Insets show higher magnification images of the two channels. n > 800 cells/condition in three different wells per day from cells transfected in 4 different days. g Quantification of total autophagic vacuoles (AV), autophagosomes (APG, yellow puncta), and autolysosomes (AUTL, red only puncta). n > 800 cells/condition in three different wells per day from cells transfected in 4 different days. Expression levels of both proteins upon transfection in N2a cells are shown in Supplemental Fig. 1h. [Serum+: Tau status effect: F(2,18) = 49.37, p < 0.0001; Serum−: Tau status effect: F(2,18) = 11.26, p = 0.0007] (h) Homogenate (HOM), Cytosol (CYT), Autophagosomes (APG), and Autolysosomes (AUT) were isolated from mouse brain and blotted for the indicated proteins. Representative immunoblot. n = 3 mice. i Quantification of enrichment (left) [Tau status effect: F(1,10) = 16.90, p = 0.0021] and recovery (right) [Tau status effect: F(1,10) = 16.92, p = 0.0021] of total tau and acetylated tau in the indicated fractions, n = 3 mice. All values are mean ± s.e.m. Statistical analysis were done using Two-way ANOVAs (panels a, c, d, g, and i) and two-tailed t-tests or Wilcoxon tests (panels e). Differences were significant with untreated or WT tau for *p < 0.05, **p < 0.01, ***p < 0.005. For clarity purposes, only relevant statistical comparisons are presented. Uncropped blots are shown in Supplemental Fig. 7.
Fig. 1 Acetylated tau is degraded by macroautophagy. a Brain slices from the mouse cortex or midbrain were incubated in the presence or absence of NH4Cl 20 mM and leupeptin 200 µM (N/L) or 3-methyladenine (3MA) 10 mM for 4 h at 37 °C and blotted for the indicated proteins. Right: Quantification of total tau (left) [Degradation pathway effect: F(2,78) = 14.31, p < 0.0001], acetylated tau (Ac-Tau; middle) [Degradation pathway effect: F(2,78) = 12.22, p < 0.0001], and fraction of tau degraded by macroautophagy (MA) [Tau status effect: F(1,52) = 507.2, p < 0.0001], n = 15 (for cortex) and 13 (for midbrain) mice per genotype. Controls of the selectivity of the acetylated antibody using brains from tau knockout mice and of the efficiency of the inhibitors are shown in Supplemental Fig. 1a, b. b–e Brain slices from wild-type (WT) and Atg7 knockout mice (ATG7KO) cortex or midbrain were incubated as in a and blotted for the indicated proteins. b Representative immunoblots. c Quantification of total and acetylated tau in two brain regions (cortex and midbrain) [Genotype effect: F(1,28) = 174, p < 0.0001]. d Changes of acetylated tau levels in both mice groups in the cortex (left) [Combined effect: F(2,42) = 4.280, p = 0.0203] and midbrain (right) [Degradation pathway effect: F(2,42) = 3.707, p = 0.0329], n = 3. Changes in total tau are shown in Supplemental Fig. 1d. e Flux of total and acetylated tau in the cortex (left) and midbrain (right) calculated as the fold increase in tau levels upon addition of N/L. f High content microscopy representative images of a mouse neuroblastoma cell line Neuro-2a (N2a) transduced with mCherry-GFP-LC3 and transfected with unmodified FLAG-wild-type Tau (WT) or acetylation-mimetic FLAG-K274,281Q tau (KQ) and maintained in the presence or absence of serum for 4 h. Nuclei are highlighted with DAPI in blue. Insets show higher magnification images of the two channels. n > 800 cells/condition in three different wells per day from cells transfected in 4 different days. g Quantification of total autophagic vacuoles (AV), autophagosomes (APG, yellow puncta), and autolysosomes (AUTL, red only puncta). n > 800 cells/condition in three different wells per day from cells transfected in 4 different days. Expression levels of both proteins upon transfection in N2a cells are shown in Supplemental Fig. 1h. [Serum+: Tau status effect: F(2,18) = 49.37, p < 0.0001; Serum−: Tau status effect: F(2,18) = 11.26, p = 0.0007] (h) Homogenate (HOM), Cytosol (CYT), Autophagosomes (APG), and Autolysosomes (AUT) were isolated from mouse brain and blotted for the indicated proteins. Representative immunoblot. n = 3 mice. i Quantification of enrichment (left) [Tau status effect: F(1,10) = 16.90, p = 0.0021] and recovery (right) [Tau status effect: F(1,10) = 16.92, p = 0.0021] of total tau and acetylated tau in the indicated fractions, n = 3 mice. All values are mean ± s.e.m. Statistical analysis were done using Two-way ANOVAs (panels a, c, d, g, and i) and two-tailed t-tests or Wilcoxon tests (panels e). Differences were significant with untreated or WT tau for *p < 0.05, **p < 0.01, ***p < 0.005. For clarity purposes, only relevant statistical comparisons are presented. Uncropped blots are shown in Supplemental Fig. 7.CC BY · PubMed Central
Fig. 2 Acetylated tau associates with CMA-active lysosomes. a Immunofluorescence staining for tau and acetylated tau (Ac-Tau) of brain sections from wild-type (WT) and CaMKinaseIIα-Cre-L2A knockout mice (L2AKO). n = 3 mice. b Immunoblot for the indicated proteins of homogenate (Hom), Cytosol (Cyt), and two lysosomal (Lys) populations with different CMA activity (CMA+ and CMA−) isolated from WT and L2AKO mice brains. Bottom left plot: Quantification of the percentage of total tau recovered in the indicated fractions. [Two-tailed t-test t4 = 3.079, p = 0.037]. Bottom middle plot: Quantification of tau levels in L2AKO mice brain homogenate relative to WT (dotted line) [Two-way ANOVA Tau status effect: F(1,12) = 90.17, p < 0.0001]. Bottom, right plot: Quantification of recovery of tau levels in lysosomes from L2AKO mice brain relative to WT [One-way ANOVA interaction effect: F(2,6) = 4.58, p = 0.061; Total vs. K274 p = 0.041] n = 3 mice. c Immunoblots of isolated lysosomes pretreated or not with protease inhibitors (PI) and incubated with increasing concentrations of tau untreated (Tau) or acetylated in vitro (Ac-Tau). d Binding and uptake of tau calculated from quantification of immunoblots as the ones shown in c [Two-way ANOVA interaction effect: F(1,13) = 49.67, p < 0.0001], n = 3 independent experiments. e, f Effect of increasing concentrations of glyceraldehyde 3-phoshpate dehydrogenase (GAPDH) in the association of tau (e) and Ac-Tau (f) with isolated liver lysosomes pre-incubated or not with protease inhibitors (PI) as labeled. The dashed line indicates the separation between running and stacking. n = 3 independent experiments per type of tau and amount of GAPDH. g Quantification of the effect of increasing concentrations of GAPDH on binding [Two way ANOVA Tau status effect: F(1,12) = 6.033, p = 0.0302] and uptake [Two-way ANOVA Tau status effect: F(1,12) = 5.815, p = 0.0328] of control and acetylated tau (note that acetylated includes all variants independently of their molecular weight). n = 3 independent experiments. h Quantification of the percentage of lysosome-associated acetylated tau detected as monomer, dimer, or higher molecular weight (HMW) complexes in the stacking of the gel upon addition of GAPDH. n = 3 independent experiments [Two-way ANOVA interaction effect: F(4,18) = 4.894, p = 0.0076]. All values are mean ± s.e.m. Differences with unmodified tau were significant for *p < 0.05 05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.
Fig. 2 Acetylated tau associates with CMA-active lysosomes. a Immunofluorescence staining for tau and acetylated tau (Ac-Tau) of brain sections from wild-type (WT) and CaMKinaseIIα-Cre-L2A knockout mice (L2AKO). n = 3 mice. b Immunoblot for the indicated proteins of homogenate (Hom), Cytosol (Cyt), and two lysosomal (Lys) populations with different CMA activity (CMA+ and CMA−) isolated from WT and L2AKO mice brains. Bottom left plot: Quantification of the percentage of total tau recovered in the indicated fractions. [Two-tailed t-test t4 = 3.079, p = 0.037]. Bottom middle plot: Quantification of tau levels in L2AKO mice brain homogenate relative to WT (dotted line) [Two-way ANOVA Tau status effect: F(1,12) = 90.17, p < 0.0001]. Bottom, right plot: Quantification of recovery of tau levels in lysosomes from L2AKO mice brain relative to WT [One-way ANOVA interaction effect: F(2,6) = 4.58, p = 0.061; Total vs. K274 p = 0.041] n = 3 mice. c Immunoblots of isolated lysosomes pretreated or not with protease inhibitors (PI) and incubated with increasing concentrations of tau untreated (Tau) or acetylated in vitro (Ac-Tau). d Binding and uptake of tau calculated from quantification of immunoblots as the ones shown in c [Two-way ANOVA interaction effect: F(1,13) = 49.67, p < 0.0001], n = 3 independent experiments. e, f Effect of increasing concentrations of glyceraldehyde 3-phoshpate dehydrogenase (GAPDH) in the association of tau (e) and Ac-Tau (f) with isolated liver lysosomes pre-incubated or not with protease inhibitors (PI) as labeled. The dashed line indicates the separation between running and stacking. n = 3 independent experiments per type of tau and amount of GAPDH. g Quantification of the effect of increasing concentrations of GAPDH on binding [Two way ANOVA Tau status effect: F(1,12) = 6.033, p = 0.0302] and uptake [Two-way ANOVA Tau status effect: F(1,12) = 5.815, p = 0.0328] of control and acetylated tau (note that acetylated includes all variants independently of their molecular weight). n = 3 independent experiments. h Quantification of the percentage of lysosome-associated acetylated tau detected as monomer, dimer, or higher molecular weight (HMW) complexes in the stacking of the gel upon addition of GAPDH. n = 3 independent experiments [Two-way ANOVA interaction effect: F(4,18) = 4.894, p = 0.0076]. All values are mean ± s.e.m. Differences with unmodified tau were significant for *p < 0.05 05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.CC BY · PubMed Central
Fig. 3 Acetylated tau has an inhibitory effect on CMA activity. a Representative images of mouse neuroblastoma cell line Neuro-2a (N2a) transduced with KFERQ-PS-Dendra2 and transfected with empty vector (Control), FLAG-wild-type tau (WT Tau) or FLAG-K274,281Q tau (KQ Tau), and maintained in the presence (+) or absence (−) of serum for 16 h. Nuclei are highlighted with DAPI in blue. Insets show higher magnification images and arrows point examples of fluorescent puncta. n > 800 cells/condition in three different wells and 4 independent experiments. b Quantification of an average number of puncta per cell section. [Two-way ANOVA Tau status effect: F(2,12) = 179.1, p < 0.0001], n > 800 cells/condition in three different wells, and n = 4 independent experiments. Controls for tau expression are shown in Supplemental Fig. 1h (protein levels) and Supplemental Fig. 3a (mRNA levels). c Degradation rates of long-lived proteins in N2a cells transfected as in a and radiolabeled for 48 h with 3H-leucine), [One-way ANOVA Tau status effect: F(2,6) = 4;619, p = 0.0610]. Right: fraction of degradation occurring in lysosomes (sensitive to inhibition of lysosomal proteolysis), [One-way ANOVA Tau status effect: F(2,6) = 14.55, p = 0.005], n = 3 independent experiments. d Immunoblot for L2A of isolated lysosomes subjected to blue-native electrophoresis after being incubated alone (No protein) or with unmodified (Tau) or in vitro acetylated tau (Ac-Tau). A 700-kDa multimeric complex and the 110-kDa monomer are shown. Right: Quantification of multimeric levels of L2A relative to those in lysosomes incubated alone. [One-way ANOVA Tau status effect: F(2,13) = 5.580, p = 0.0178], n = 4 independent experiments. e Lysosomes incubated and processed under the same conditions as in d but in the presence or absence of hsc70. f Immunoblot for tau of the GST-pulldowns of GST-hsc70 incubated with tau or Ac-Tau at neutral pH for 30 min at 37 °C. Input (Ipt): 1/10 of tau added to the incubation. Right: Quantification of tau bound to Hsc70. [Two-tailed t-test t4 = 4.432, p = 0.0114], n = 3. g Samples incubated as in f but at different pH. Right: Quantification of tau bound to hsc70 [Two-way ANOVA Tau status effect: F(1,18) = 10.85, p = 0.0040], n = 4 independent experiments. h Tau or K280Q tau binding assay to immobilized hsc70 determined by ELISA at the indicated pH. See also Supplemental Fig. 3b and c for binding assays at intermediate pH. n = 6 (in 2 independent experiments). i Summary plot of the binding assay at all tested pH for tau and acetylated tau (Ac-Tau). [Two-way ANOVA Tau status effect: F(1,8) = 42.10, p = 0.0002]. n = 6 (in 2 independent experiments). j Immunoblots of lysosomes from starved rat livers, pretreated or not with protease inhibitors (PI) and/or NH4Cl 20 mM for 10 min at 4 °C and then incubated with tau (left) or Ac-Tau (middle). n = 3 independent experiments. k Quantification of tau proteins binding and uptake by lysosomes. [Two-way ANOVA Tau status effect: F(1,17) = 17.22, p = 0.0013], n = 3 independent experiments. All values are mean ± s.e.m. Differences with control or unmodified tau were significant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.
Fig. 3 Acetylated tau has an inhibitory effect on CMA activity. a Representative images of mouse neuroblastoma cell line Neuro-2a (N2a) transduced with KFERQ-PS-Dendra2 and transfected with empty vector (Control), FLAG-wild-type tau (WT Tau) or FLAG-K274,281Q tau (KQ Tau), and maintained in the presence (+) or absence (−) of serum for 16 h. Nuclei are highlighted with DAPI in blue. Insets show higher magnification images and arrows point examples of fluorescent puncta. n > 800 cells/condition in three different wells and 4 independent experiments. b Quantification of an average number of puncta per cell section. [Two-way ANOVA Tau status effect: F(2,12) = 179.1, p < 0.0001], n > 800 cells/condition in three different wells, and n = 4 independent experiments. Controls for tau expression are shown in Supplemental Fig. 1h (protein levels) and Supplemental Fig. 3a (mRNA levels). c Degradation rates of long-lived proteins in N2a cells transfected as in a and radiolabeled for 48 h with 3H-leucine), [One-way ANOVA Tau status effect: F(2,6) = 4;619, p = 0.0610]. Right: fraction of degradation occurring in lysosomes (sensitive to inhibition of lysosomal proteolysis), [One-way ANOVA Tau status effect: F(2,6) = 14.55, p = 0.005], n = 3 independent experiments. d Immunoblot for L2A of isolated lysosomes subjected to blue-native electrophoresis after being incubated alone (No protein) or with unmodified (Tau) or in vitro acetylated tau (Ac-Tau). A 700-kDa multimeric complex and the 110-kDa monomer are shown. Right: Quantification of multimeric levels of L2A relative to those in lysosomes incubated alone. [One-way ANOVA Tau status effect: F(2,13) = 5.580, p = 0.0178], n = 4 independent experiments. e Lysosomes incubated and processed under the same conditions as in d but in the presence or absence of hsc70. f Immunoblot for tau of the GST-pulldowns of GST-hsc70 incubated with tau or Ac-Tau at neutral pH for 30 min at 37 °C. Input (Ipt): 1/10 of tau added to the incubation. Right: Quantification of tau bound to Hsc70. [Two-tailed t-test t4 = 4.432, p = 0.0114], n = 3. g Samples incubated as in f but at different pH. Right: Quantification of tau bound to hsc70 [Two-way ANOVA Tau status effect: F(1,18) = 10.85, p = 0.0040], n = 4 independent experiments. h Tau or K280Q tau binding assay to immobilized hsc70 determined by ELISA at the indicated pH. See also Supplemental Fig. 3b and c for binding assays at intermediate pH. n = 6 (in 2 independent experiments). i Summary plot of the binding assay at all tested pH for tau and acetylated tau (Ac-Tau). [Two-way ANOVA Tau status effect: F(1,8) = 42.10, p = 0.0002]. n = 6 (in 2 independent experiments). j Immunoblots of lysosomes from starved rat livers, pretreated or not with protease inhibitors (PI) and/or NH4Cl 20 mM for 10 min at 4 °C and then incubated with tau (left) or Ac-Tau (middle). n = 3 independent experiments. k Quantification of tau proteins binding and uptake by lysosomes. [Two-way ANOVA Tau status effect: F(1,17) = 17.22, p = 0.0013], n = 3 independent experiments. All values are mean ± s.e.m. Differences with control or unmodified tau were significant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.CC BY · PubMed Central
Fig. 4 Acetylated tau and endosomal microautophagy. a Immunoblots of late endosomes (LE) isolated from tau-null mice brains, pretreated or not with protease inhibitors (PI), and incubated with tau or in vitro acetylated tau (Ac-tau). Tau input is 1/5 of the protein added. b Quantification of endosomal binding [Two-tailed t-test t7 = 13.80, p < 0.0001] and uptake [Two-tailed t-test t7 = 3.239, p = 0.0143] of tau proteins from blots as in a. n = 3 mice. c Immunoblot with the indicated antibodies of homogenate (Hom) and late endosomes (LE) isolated from mice brain. A dashed line indicates the separation between running and stacking in the gel. The same homogenate and LE fractions were loaded in triplicate in a membrane and strips of the membrane were separately incubated with each of the antibodies to allow for comparison among antibodies. d Immunoblot for the indicated antibodies of Hom, cytosol (Cyt), and LE isolated from brains of wild-type (WT) and L2A knock-out mice (L2A KO). Dashed lines as in c. Right: quantification of the amount of total and acetylated tau in monomer [Two-way ANOVA genotype effect: F(1,8) = 10.56, p = 0.0117] and in high molecular weight (HMW) complexes [Two-tailed t-test t4 = 2.694, p = 0.0545]. n = 4 mice. e Immunoblot for total and acetylated tau in CSF isolated from wild-type and L2AKO mice. n = 3 mice per genotype were pooled for each immunoblot; the 2 samples shown here correspond to isolations done in 2 separate days. f Immunoblot for the indicated forms of tau of lysates and culture media from iPSC-derived human neurons upon stimulation with KCl for 30 min. Note: saturated bands are shown for the lysates in the PHF-1 membrane to illustrate the small amount of phosphorylated tau detected in the media. n = 4 different experiments performed in 2 different iPSC cell lines. g Left: Scheme illustrating rerouting of tau towards LE/MVB upon blockage of CMA and extracellular release of tau after fusion of LE/MVB with the plasma membrane. APG: autophagosome, Lys: lysosome. Right: Quantification of extracellular tau using ELISA upon blockage of the various autophagy pathways in N2a cells expressing human P301LTau. Vps4: VPS4 knock-down, L2A: L2A knock-down, Atg7: ATG7 knock-down, L2A + Vps4: a combination of L2A and VPS4 knock-down. The efficiency of the different knock-downs is shown in Supplemental Fig. 4c. Values are expressed as the fold on PGK (Control). [One-way ANOVA F(4,37) = 9.542, p < 0.0001]. n = 8, 10, 9, 9, 6 (in order of genotype shown in the graph) independent experiments. All values are mean ± s.e.m. Differences with control or unmodified tau were significant for *p < 0.05, **p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.
Fig. 4 Acetylated tau and endosomal microautophagy. a Immunoblots of late endosomes (LE) isolated from tau-null mice brains, pretreated or not with protease inhibitors (PI), and incubated with tau or in vitro acetylated tau (Ac-tau). Tau input is 1/5 of the protein added. b Quantification of endosomal binding [Two-tailed t-test t7 = 13.80, p < 0.0001] and uptake [Two-tailed t-test t7 = 3.239, p = 0.0143] of tau proteins from blots as in a. n = 3 mice. c Immunoblot with the indicated antibodies of homogenate (Hom) and late endosomes (LE) isolated from mice brain. A dashed line indicates the separation between running and stacking in the gel. The same homogenate and LE fractions were loaded in triplicate in a membrane and strips of the membrane were separately incubated with each of the antibodies to allow for comparison among antibodies. d Immunoblot for the indicated antibodies of Hom, cytosol (Cyt), and LE isolated from brains of wild-type (WT) and L2A knock-out mice (L2A KO). Dashed lines as in c. Right: quantification of the amount of total and acetylated tau in monomer [Two-way ANOVA genotype effect: F(1,8) = 10.56, p = 0.0117] and in high molecular weight (HMW) complexes [Two-tailed t-test t4 = 2.694, p = 0.0545]. n = 4 mice. e Immunoblot for total and acetylated tau in CSF isolated from wild-type and L2AKO mice. n = 3 mice per genotype were pooled for each immunoblot; the 2 samples shown here correspond to isolations done in 2 separate days. f Immunoblot for the indicated forms of tau of lysates and culture media from iPSC-derived human neurons upon stimulation with KCl for 30 min. Note: saturated bands are shown for the lysates in the PHF-1 membrane to illustrate the small amount of phosphorylated tau detected in the media. n = 4 different experiments performed in 2 different iPSC cell lines. g Left: Scheme illustrating rerouting of tau towards LE/MVB upon blockage of CMA and extracellular release of tau after fusion of LE/MVB with the plasma membrane. APG: autophagosome, Lys: lysosome. Right: Quantification of extracellular tau using ELISA upon blockage of the various autophagy pathways in N2a cells expressing human P301LTau. Vps4: VPS4 knock-down, L2A: L2A knock-down, Atg7: ATG7 knock-down, L2A + Vps4: a combination of L2A and VPS4 knock-down. The efficiency of the different knock-downs is shown in Supplemental Fig. 4c. Values are expressed as the fold on PGK (Control). [One-way ANOVA F(4,37) = 9.542, p < 0.0001]. n = 8, 10, 9, 9, 6 (in order of genotype shown in the graph) independent experiments. All values are mean ± s.e.m. Differences with control or unmodified tau were significant for *p < 0.05, **p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.CC BY · PubMed Central
Fig. 5 Changes in the association of tau with autophagic and lysosomal compartments in Alzheimer’s disease patient brains. a Immunoblots for the indicated proteins of homogenates (Hom), cytosol (Cyt), and two populations of lysosomes (Lys) with different CMA activity (CMA+ and CMA−) isolated from the frontal area of brains from patients with Alzheimer’s Disease (AD, n = 6) and non-neurological patients of matching age (Control, n = 7). b Pictures of CMA-active lysosomes isolated from control (n = 3) or AD (n = 3) patients’ brains and subjected to electron microscopy. Right: higher magnification inserts. Red arrows: undegraded dense lipofuscin-like material. Differences noted in the images were reproducible in the 3 brains. c Immunoblot for acetylated tau (Ac-Tau) in lysosomal matrices from control and AD patients. Right: Quantification of the amount of acetylated tau (Ac-Tau) internalized in AD patients’ lysosomes relative to control [Two-tailed t-test t4 = 6.831, p = 0.0024]. n = 3 samples (1 per brain) per group. d Immunoblot from L2A of the blue-native electrophoresis of lysosomes isolated as in a and incubated alone (No substrate) or in the presence of 1 µg of purified alpha-synuclein (Alpha syn). Two different individuals per diagnosis are shown. Multimer: indicates the 700-kDa multimeric translocation complex. Monomer: insert of the monomer run in a different gel. n = 6 control and 6 AD patient brains. e Quantification of multimeric L2A levels relative to those in control lysosomes in absence of substrate [Two-tailed t-test t11 = 4.936, p = 0.0004]. n = 7 control and 6 AD patient brains. f Quantification of multimeric L2A levels in absence of substrate (N.S.) or upon substrate (α-syn) presentation. Top changes of multimeric L2A for individual subjects. Bottom: Fold increase of L2A multimers upon substrate presentation [Two-tailed t-test t11 = 3.607, p = 0.0041]. n = 7 controls and 6 AD patient brains. g Immunoblots for the indicated proteins of homogenates (Hom), cytosol (Cyt), autophagic vacuoles (AV), and late endosomes (LE) isolated from patients with Alzheimer’s Disease (AD) and non-neurological patients of matching age (Control). n = 3 samples (1 per brain) per condition. h Quantification of the abundance of acetylated tau in autophagic vesicles [Two-tailed t-test t4 = 2.805, p = 0.0486]. n = 3 samples (1 per brain) per group. I, j Quantification of the ratio of acetylated to total tau in the indicated fraction (i) and of the abundance of the high molecular weight (HMW) acetylated tau species in LE (j). [Two-tailed t-test t4 = 8.719, p = 0.001]. n = 3 samples (1 per brain) per group. All values are mean ± s.e.m. Differences with control were significant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.
Fig. 5 Changes in the association of tau with autophagic and lysosomal compartments in Alzheimer’s disease patient brains. a Immunoblots for the indicated proteins of homogenates (Hom), cytosol (Cyt), and two populations of lysosomes (Lys) with different CMA activity (CMA+ and CMA−) isolated from the frontal area of brains from patients with Alzheimer’s Disease (AD, n = 6) and non-neurological patients of matching age (Control, n = 7). b Pictures of CMA-active lysosomes isolated from control (n = 3) or AD (n = 3) patients’ brains and subjected to electron microscopy. Right: higher magnification inserts. Red arrows: undegraded dense lipofuscin-like material. Differences noted in the images were reproducible in the 3 brains. c Immunoblot for acetylated tau (Ac-Tau) in lysosomal matrices from control and AD patients. Right: Quantification of the amount of acetylated tau (Ac-Tau) internalized in AD patients’ lysosomes relative to control [Two-tailed t-test t4 = 6.831, p = 0.0024]. n = 3 samples (1 per brain) per group. d Immunoblot from L2A of the blue-native electrophoresis of lysosomes isolated as in a and incubated alone (No substrate) or in the presence of 1 µg of purified alpha-synuclein (Alpha syn). Two different individuals per diagnosis are shown. Multimer: indicates the 700-kDa multimeric translocation complex. Monomer: insert of the monomer run in a different gel. n = 6 control and 6 AD patient brains. e Quantification of multimeric L2A levels relative to those in control lysosomes in absence of substrate [Two-tailed t-test t11 = 4.936, p = 0.0004]. n = 7 control and 6 AD patient brains. f Quantification of multimeric L2A levels in absence of substrate (N.S.) or upon substrate (α-syn) presentation. Top changes of multimeric L2A for individual subjects. Bottom: Fold increase of L2A multimers upon substrate presentation [Two-tailed t-test t11 = 3.607, p = 0.0041]. n = 7 controls and 6 AD patient brains. g Immunoblots for the indicated proteins of homogenates (Hom), cytosol (Cyt), autophagic vacuoles (AV), and late endosomes (LE) isolated from patients with Alzheimer’s Disease (AD) and non-neurological patients of matching age (Control). n = 3 samples (1 per brain) per condition. h Quantification of the abundance of acetylated tau in autophagic vesicles [Two-tailed t-test t4 = 2.805, p = 0.0486]. n = 3 samples (1 per brain) per group. I, j Quantification of the ratio of acetylated to total tau in the indicated fraction (i) and of the abundance of the high molecular weight (HMW) acetylated tau species in LE (j). [Two-tailed t-test t4 = 8.719, p = 0.001]. n = 3 samples (1 per brain) per group. All values are mean ± s.e.m. Differences with control were significant for *p < 0.05, **p < 0.01, ***p < 0.005. Uncropped blots are shown in Supplemental Fig. 7.CC BY · PubMed Central
Fig. 6 CMA deficiency accelerates Tau spreading. a Example of immunofluorescence for human tau (huTau-red) and GFP (Green) of the whole hippocampal formation in coronal section. Bottom pictures are representative pictures of donor [GFP+/huTau+] and recipient [GFP−/huTau+] cells. Scale bars: top: 100 µm; bottom 20 µm. n = 20 mice (10 WT and 10 L2AKO). b Representative images of Tau and GFP levels in CA1 (injection site) and CA3 (spreading site) in WT and L2AKO mice at 8 weeks after surgery. Scale bar: 50 µm. n = 4 mice per genotype. c Distribution of GFP intensity in donor cells (with kernel density estimation) in WT and L2AKO mice. d Distribution of human Tau intensity in donor cells (with kernel density estimation) in WT and L2AKO mice [Two-tailed t-test t553 = 16.113, p = 3.69 × 10−48]. e Number of recipient cells over time [Two-way ANOVA genotype effect: F(1,14) = 7.668, p = 0.0151]. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. f Left: scatterplot showing the average number of recipient versus donor cells per mouse. Dotted lines are the linear regression per genotype. Right: slopes of the linear regression between recipient and donor cells per genotype. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. h Scatterplot showing the average intensity of acetylated tau in donor cells versus the average number of recipient cells per mouse. The dotted line is the mean linear regression +/−95% confidence interval (gray zone). g Levels of human tau (huTau) and K174 acetylated tau (ac-Tau) in recipient cells between WT and L2AKO mice. n = 4 mice per genotype. Scale bar: 50 µm. All values are mean ± s.e.m. except otherwise specified. Differences with WT mice were significant for *p < 0.05, ***p < 0.0005.
Fig. 6 CMA deficiency accelerates Tau spreading. a Example of immunofluorescence for human tau (huTau-red) and GFP (Green) of the whole hippocampal formation in coronal section. Bottom pictures are representative pictures of donor [GFP+/huTau+] and recipient [GFP−/huTau+] cells. Scale bars: top: 100 µm; bottom 20 µm. n = 20 mice (10 WT and 10 L2AKO). b Representative images of Tau and GFP levels in CA1 (injection site) and CA3 (spreading site) in WT and L2AKO mice at 8 weeks after surgery. Scale bar: 50 µm. n = 4 mice per genotype. c Distribution of GFP intensity in donor cells (with kernel density estimation) in WT and L2AKO mice. d Distribution of human Tau intensity in donor cells (with kernel density estimation) in WT and L2AKO mice [Two-tailed t-test t553 = 16.113, p = 3.69 × 10−48]. e Number of recipient cells over time [Two-way ANOVA genotype effect: F(1,14) = 7.668, p = 0.0151]. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. f Left: scatterplot showing the average number of recipient versus donor cells per mouse. Dotted lines are the linear regression per genotype. Right: slopes of the linear regression between recipient and donor cells per genotype. n = 3, 3, and 4 mice per genotype at 2, 4, and 8 weeks, respectively. h Scatterplot showing the average intensity of acetylated tau in donor cells versus the average number of recipient cells per mouse. The dotted line is the mean linear regression +/−95% confidence interval (gray zone). g Levels of human tau (huTau) and K174 acetylated tau (ac-Tau) in recipient cells between WT and L2AKO mice. n = 4 mice per genotype. Scale bar: 50 µm. All values are mean ± s.e.m. except otherwise specified. Differences with WT mice were significant for *p < 0.05, ***p < 0.0005.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Research works printed but not linked: 1

  1. Morris, M., Maeda, S., Vossel, K. & Mucke, L. The many faces of Tau. Neuron 70, 410–426 (2011). · DOI · Paper page

Cited by

Sorted by citations

Items 101–200 of 223

Related

See all

Metadata

Authors
Caballero, B., Bourdenx, M., Luengo, E., Diaz, A., Sohn, P. D., Chen, X., Wang, C., Juste, Y. R., Wegmann, S., Patel, B., Young, Z. T., Kuo, S. Y., Rodriguez-Navarro, J. A., Shao, H., Lopez, M. G., Karch, C. M., Goate, A. M., Gestwicki, J. E., Hyman, B. T., Gan, L., & Cuervo, A. M.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Centre National de la Recherche Scientifique (FR)
  • Weill Cornell Medicine (US)
  • Harvard University (US)
  • University of California, San Francisco (US)
  • Washington University in St. Louis (US)
  • Icahn School of Medicine at Mount Sinai (US)
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-04-14
Volume
12
Issue
1
Pages
2238-2238
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-22501-9
PMC
PMC8047017
OpenAlex
W3154991192
Cited by
223
References
92
Citations by year
2026: 29 · 2025: 61 · 2024: 30 · 2023: 47 · 2022: 42 · 2021: 14
FWCI
20.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, other-oa)
Funders
  • Fundación Tatiana Pérez de Guzmán el Bueno (Fellowship)
  • U.S. Department of Health & Human Services | National Institutes of Health (T32 GM007491)
  • Charles H. Revson Foundation (CP13-00234)
  • Rainwaters Foundation
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG05681, AG058674, AG036884, AG021904, AG054108, AG031782, AG038072)
  • Rainwaters Foundation JPB Foundation
  • U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS100717)
  • Rainwaters Foundation Backus Foundation JPB Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords
tau acetylation, chaperone-mediated autophagy, tauopathy, tau degradation, macroautophagy, microautophagy, lysosomes, cell-to-cell transmission, neurodegeneration
MeSH terms
Chaperone-Mediated Autophagy, Acetylation, Animals, Brain, Female, Humans, Male, Mice, Inbred C57BL, Neurons, tau Proteins, Tauopathies, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review